» Articles » PMID: 26705086

Adoptive T Cell Therapies: A Comparison of T Cell Receptors and Chimeric Antigen Receptors

Overview
Specialty Pharmacology
Date 2015 Dec 26
PMID 26705086
Citations 129
Authors
Affiliations
Soon will be listed here.
Abstract

The tumor-killing properties of T cells provide tremendous opportunities to treat cancer. Adoptive T cell therapies have begun to harness this potential by endowing a functionally diverse repertoire of T cells with genetically modified, tumor-specific recognition receptors. Normally, this antigen recognition function is mediated by an αβ T cell receptor (TCR), but the dominant therapeutic forms currently in development are synthetic constructs called chimeric antigen receptors (CARs). While CAR-based adoptive cell therapies are already showing great promise, their basic mechanistic properties have been studied in less detail compared with those of αβ TCRs. In this review, we compare and contrast various features of TCRs versus CARs, with a goal of highlighting issues that need to be addressed to fully exploit the therapeutic potential of both.

Citing Articles

T-regulatory cells for the treatment of autoimmune diseases.

Fisher M, Sennikov S Front Immunol. 2025; 16:1511671.

PMID: 39967659 PMC: 11832489. DOI: 10.3389/fimmu.2025.1511671.


Targeting CEA in metastatic triple negative breast cancer with image-guided radiation followed by Fab-mediated chimeric antigen receptor (CAR) T-cell therapy.

Aniogo E, Kujawski M, Awuah D, Cha S, Espinosa R, Hui S Front Immunol. 2025; 15:1499471.

PMID: 39759518 PMC: 11695362. DOI: 10.3389/fimmu.2024.1499471.


Breaking barriers: advancing cellular therapies in autoimmune disease management.

Fu Y, Feng C, Qin S, Xing Z, Liu C, Liu Z Front Immunol. 2024; 15:1503099.

PMID: 39676874 PMC: 11638217. DOI: 10.3389/fimmu.2024.1503099.


Unlocking Apoptotic Pathways: Overcoming Tumor Resistance in CAR-T-Cell Therapy.

Zhang Z, Su M, Jiang P, Wang X, Tong X, Wu G Cancer Med. 2024; 13(19):e70283.

PMID: 39377542 PMC: 11459502. DOI: 10.1002/cam4.70283.


Human TCR repertoire in cancer.

Chen L, Hu Y, Zheng B, Luo L, Su Z Cancer Med. 2024; 13(17):e70164.

PMID: 39240157 PMC: 11378360. DOI: 10.1002/cam4.70164.


References
1.
Holler P, Chlewicki L, Kranz D . TCRs with high affinity for foreign pMHC show self-reactivity. Nat Immunol. 2002; 4(1):55-62. DOI: 10.1038/ni863. View

2.
Bowerman N, Crofts T, Chlewicki L, Do P, Baker B, Garcia K . Engineering the binding properties of the T cell receptor:peptide:MHC ternary complex that governs T cell activity. Mol Immunol. 2009; 46(15):3000-8. PMC: 2773466. DOI: 10.1016/j.molimm.2009.06.012. View

3.
Boomer J, Green J . An enigmatic tail of CD28 signaling. Cold Spring Harb Perspect Biol. 2010; 2(8):a002436. PMC: 2908766. DOI: 10.1101/cshperspect.a002436. View

4.
Morgan R, Chinnasamy N, Abate-Daga D, Gros A, Robbins P, Zheng Z . Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother. 2013; 36(2):133-51. PMC: 3581823. DOI: 10.1097/CJI.0b013e3182829903. View

5.
Purbhoo M, Irvine D, Huppa J, Davis M . T cell killing does not require the formation of a stable mature immunological synapse. Nat Immunol. 2004; 5(5):524-30. DOI: 10.1038/ni1058. View